Naldemedine
Brand names: Symproic · Active ingredient: Naldemedine Tosylate
In short: SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
What is Naldemedine used for?
SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
Naldemedine dosage
Alteration of analgesic dosing regimen prior to initiating SYMPROIC is not required.
Patients receiving opioids for less than 4 weeks may be less responsive to SYMPROIC .
Discontinue SYMPROIC if treatment with the opioid pain medication is also discontinued.
The recommended dosage of SYMPROIC is 0.2 mg orally once daily with or without food.
How to take Naldemedine — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Administration
Advise patients to discontinue SYMPROIC if treatment with the opioid pain medication is also discontinued.
Gastrointestinal Perforation
Advise patients to discontinue SYMPROIC and to promptly seek medical attention if they develop unusually severe, persistent or worsening abdominal pain .
Opioid Withdrawal
Advise patients that clusters of symptoms consistent with opioid withdrawal may occur while taking SYMPROIC and to contact their healthcare provider if these symptoms occur .
Pregnancy
Advise females of reproductive potential, who become pregnant or are planning to become pregnant, that the use of SYMPROIC during pregnancy may precipitate opioid withdrawal in a fetus due to the undeveloped blood-brain barrier .
Lactation
Advise women that breastfeeding is not recommended during treatment with SYMPROIC and for 3 days after the final dose .
Warnings & precautions
Do not take this medicine if: SYMPROIC is contraindicated in:
Patients with known or suspected gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation .
Patients with a history of a hypersensitivity reaction to naldemedine. Reactions have included bronchospasm and rash .
Cases of gastrointestinal (GI) perforation have been reported with use of another peripherally acting opioid antagonist, including SYMPROIC. Postmarketing cases of GI perforation, including fatal cases, were reported when SYMPROIC was used in patients at risk of GI perforation (e.g., GI cancer, past GI surgery, diverticulitis, chemotherapy/radiation). SYMPROIC is contraindicated in patients with known or suspected gastrointestinal obstruction or in patients at risk of recurrent obstruction. Take into account the overall risk-benefit profile when using SYMPROIC in patients with these conditions or other conditions which might result in impaired integrity of the gastrointestinal tract wall (e.g., Crohn's disease). Monitor for the development of severe, persistent, or worsening abdominal pain; discontinue SYMPROIC in patients who develop this symptom.
Clusters of symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, increased lacrimation, hot flush/flushing, pyrexia, sneezing, feeling cold, abdominal pain, diarrhea, nausea, and vomiting have occurred in patients treated with SYMPROIC .
Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal or reduced analgesia. Take into account the overall risk-benefit profile when using SYMPROIC in such patients. Monitor for symptoms of opioid withdrawal in such patients.
Naldemedine side effects
Serious and important adverse reactions described elsewhere in labeling include:
Gastrointestinal perforation
Opioid withdrawal
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to SYMPROIC in 1163 patients in clinical trials, including 487 patients with exposures greater than six months and 203 patients with exposures of 12 months.
The following safety data are derived from three double-blind, placebo-controlled trials in patients with OIC and chronic non-cancer pain: two 12-week studies (Studies 1 and 2) and one 52-week study (Study 3) .
In Studies 1 and 2, patients on laxatives were required to discontinue their use prior to study enrollment. All patients were restricted to bisacodyl rescue treatment during the study. In Study 3, approximately 60% of patients in both treatment groups were on a laxative regimen at baseline; patients were allowed to continue using their laxative regimen throughout the study duration. The safety profile of SYMPROIC relative to placebo was similar regardless of laxative use.
Tables 1 and 2 list common adverse reactions occurring in at least 2% of patients receiving SYMPROIC and at an incidence greater than placebo. Table 1 shows pooled 12-week data from Studies 1 and 2. …
Drug interactions
Table 3 includes drugs with clinically important drug interactions with SYMPROIC and instructions for preventing or managing the interaction.
Strong CYP3A Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort)
Clinical Impact | Significant decrease in plasma naldemedine concentrations, which may reduce efficacy
Intervention | Avoid use of SYMPROIC with strong CYP3A inducers.
Other Opioid Antagonists
Clinical Impact | Potential for additive effect of opioid receptor antagonism and increased risk of opioid withdrawal.
Intervention | Avoid use of SYMPROIC with another opioid antagonist.
Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors
Clinical Impact | Increase in plasma naldemedine concentrations
Intervention | Monitor for potential naldemedine-related adverse reactions .
P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil)
Clinical Impact | Increase in plasma naldemedine concentrations
Intervention | Monitor for potential naldemedine-related adverse reactions .
About this medicine
SYMPROIC (naldemedine), an opioid antagonist, contains naldemedine tosylate as the active ingredient.
The chemical name for naldemedine tosylate is: 17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid.
The structural formula is:
The empirical formula for naldemedine tosylate is C32H34N4O6∙C7H8O3S and the molecular weight is 742.84.
Naldemedine tosylate is a white to light tan powder, soluble in dimethylsulfoxide and methanol, slightly soluble in alcohol and water, and independent of pH.
SYMPROIC (naldemedine) tablets for oral use contain 0.2 mg naldemedine (equivalent to 0.26 mg of naldemedine tosylate).
Excipients are: D-mannitol, croscarmellose sodium, magnesium stearate, hypromellose, talc, and yellow ferric oxide.
How it works: Naldemedine is an opioid antagonist with binding affinities for mu-, delta-, and kappa-opioid receptors. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b1a1256c-a1eb-4abe-ab1e-30e4711afd16. Read the full official label on DailyMed.
Related medicines
Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine